hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06300294, orgStudyIdInfo id: AIBU-SBF-AYN-3, briefTitle: Acute Coronary Syndrome and Acupressure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-04-15, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Abant Izzet Baysal University, class: OTHER, descriptionModule briefSummary: This study aims to examine the effect of acupressure on physiological parameters and anxiety levels in individuals diagnosed with Acute Coronary Syndrome (ACS).H1-1: Acupressure applied to individuals diagnosed with ACS has an effect on the level of anxiety.H1-2: Acupressure applied to individuals diagnosed with ACS has an effect on blood pressure.H1-3: Acupressure applied to individuals diagnosed with ACS has an effect on heart rate.H1-4: Acupressure applied to individuals diagnosed with ACS has an effect on respiratory rate.H1-5: Acupressure applied to individuals diagnosed with ACS has an effect on the pain level.H1-6: Acupressure applied to individuals diagnosed with ACS has an effect on cortisol levels., conditionsModule conditions: Acute Coronary Syndrome, conditions: Nursing, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: experimental and control, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: TRIPLE, maskingDescription: Since block randomization will be used in the study, the research director and the individuals who meet the study inclusion criteria will not know which group they will be in during the preliminary evaluation process of the study. However, the person analyzing the data will not know which group the data belongs to., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 38, type: ESTIMATED, armsInterventionsModule interventions name: acupressure, outcomesModule primaryOutcomes measure: means of blood pressure, primaryOutcomes measure: means of hear rate, primaryOutcomes measure: means of respiratory rate, primaryOutcomes measure: means of cortisol., secondaryOutcomes measure: means of subjective anxiety scores., secondaryOutcomes measure: means of subjective pain scores., secondaryOutcomes measure: electrocardiography evaluation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06300268, orgStudyIdInfo id: CSPL/PL/2023/004, briefTitle: Advapro Coronary Stent System in Coronary Artery Diseased Patients., acronym: RESTORE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Advanced MedTech Solutions Pvt. Ltd., class: OTHER, descriptionModule briefSummary: A Prospective, Multicentre, Pilot Study to Evaluate the Safety and Performance of the AdvaPro Sirolimus Eluting Coronary Stent System in Coronary Artery Stenosis in Indian and European Population.To evaluate the performance of AdvaPro Sirolimus Eluting Stent follow up indicated by MACE at 9 months.Of the 120, 40 patients will be assigned to European population and 80 patients will be assigned to Indian population. QCA is applicable for only in sub-strategy participants at baseline and 9 month follow-up visit.A QCA Analysis will be performed on minimum 48 patients in Indian population only.Interval(Days) for patients visit at Day 0, Day 30±6, Day 180±8, Day 270±10 and Day 360±14., conditionsModule conditions: Coronary Artery Disease, conditions: De Novo Stenosis Lesion, conditions: Coronary Stent Implantation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Pilot Study (Open Label), primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: AdvaPro Sirolimus Eluting Coronary Stent System, outcomesModule primaryOutcomes measure: Composite Endpoint, secondaryOutcomes measure: Incidence of DOCE, secondaryOutcomes measure: Incidence of POCE, secondaryOutcomes measure: Incidence of MACE, secondaryOutcomes measure: Target vessel failure (TVF), secondaryOutcomes measure: Non-Target Vessel related Myocardial Infarction, secondaryOutcomes measure: Stent thrombosis, secondaryOutcomes measure: Device success, secondaryOutcomes measure: Procedural Success, secondaryOutcomes measure: Acute Device Success, otherOutcomes measure: For QCA Group, otherOutcomes measure: For QCA Group, otherOutcomes measure: For QCA Group, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06300255, orgStudyIdInfo id: IRB 00166616, briefTitle: Evaluation of the H.O.O.V.E.S. Healing Intensives Program, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-22, primaryCompletionDateStruct date: 2029-02-01, completionDateStruct date: 2029-02-01, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: VA Salt Lake City Health Care System, class: FED, descriptionModule briefSummary: The aim of this study is to measure the impact of these H.O.O.V.E.S. healing intensives on Veteran participants using several psychological instruments. The investigators are planning to administer the demographic questionnaires and psychological instruments to Veteran participants before the healing intensives. Psychological instruments will be administered immediately pre-intervention, pre- and post-session for each session, post-intervention, 90, 120 and 360 days post-intervention. The primary aim is to assess for statistically significant changes pre- to post session and pre- to post-intervention., conditionsModule conditions: Anxiety, conditions: PTSD, conditions: Depression, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: H.O.O.V.E.S. Healing Intensives, outcomesModule primaryOutcomes measure: Mean Difference in AAQII pre- to post-session and pre- to post-intervention, primaryOutcomes measure: Mean Difference in PANAS pre- to post-session and pre- to post-intervention, primaryOutcomes measure: Mean Difference in STAI pre- to post-session and pre- to post-intervention, primaryOutcomes measure: Mean Difference in PCL pre- to post-session and pre- to post-intervention, primaryOutcomes measure: Mean Difference in BDI pre- to post-session and pre- to post-intervention, primaryOutcomes measure: Mean Difference in PTGI pre- to post-session and pre- to post-intervention, primaryOutcomes measure: Mean Difference in B-SCS pre- to post-session and pre- to post-intervention, secondaryOutcomes measure: Mean Difference in AAQII pre- to post-session, secondaryOutcomes measure: Mean Difference in PANAS pre- to post-session, secondaryOutcomes measure: Mean Difference in STAI pre- to post-session, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: George E. Wahlen Department of Veterans Affairs Medical Center, city: Salt Lake City, state: Utah, zip: 84148, country: United States, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06300242, orgStudyIdInfo id: UP-23-00859, briefTitle: Incentives for Influenza Vaccination, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-17, primaryCompletionDateStruct date: 2024-01-24, completionDateStruct date: 2024-02-29, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: University of Southern California, class: OTHER, collaborators name: J-PAL North America, descriptionModule briefSummary: In this work, we are assessing the impact of messaging with or without a $50 financial incentive on influenza vaccination rates in a county health system. Our main hypothesis is that a message with a $50 financial incentive will increase vaccination rates relative to a control/"treatment as usual" group. We further hypothesize that the financial incentive will increase vaccination rates relative to the message only arm., conditionsModule conditions: Influenza Vaccination, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 66000, type: ESTIMATED, armsInterventionsModule interventions name: Reminders, interventions name: Financial Incentive, interventions name: Placebo, outcomesModule primaryOutcomes measure: Vaccination status at 1 week, secondaryOutcomes measure: Vaccination status at 2 weeks, secondaryOutcomes measure: Vaccination status at 1 month, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Contra Costa Health Services, city: Martinez, state: California, zip: 94553, country: United States, geoPoint lat: 38.01937, lon: -122.13413, hasResults: False
protocolSection identificationModule nctId: NCT06300229, orgStudyIdInfo id: 2023-508325-27-00, briefTitle: NAPO - Novel Approach for Oligospermia, acronym: NAPO, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Martin Blomberg Jensen, class: OTHER, descriptionModule briefSummary: This randomized controlled trial aims to assess whether treatment with denosumab can improve semen quality in infertile men selected by serum anti-mullerian hormone (AMH) as a positive predictive biomarker, and with severely impaired semen quality (concentrations between 0.01 million/mL to 2 million/mL)., conditionsModule conditions: Infertility, Male, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: Denosumab, interventions name: sodium chloride, outcomesModule primaryOutcomes measure: The difference in sperm concentration (million pr. mL) on day 80, secondaryOutcomes measure: The difference in semen quality (total sperm count, motile sperm, progressive motile sperm and morphologically normal sperm) between baseline and two semen samples delivered at day 80 and day 83 after inclusion, secondaryOutcomes measure: The change/differences in number of pregnancies achieved before day 180, secondaryOutcomes measure: The difference in the number of miscarriages throughout the trial before day 180, secondaryOutcomes measure: The change/difference in serum levels of follicle stimulating hormone (FSH) on day 80, secondaryOutcomes measure: The change/difference in serum levels of reproductive hormone luteinizing hormone (LH) on day 80, secondaryOutcomes measure: The change/difference in serum levels of reproductive hormone AMH on day 80, secondaryOutcomes measure: The change/difference in serum levels of reproductive hormone Inhibin B on day 80, otherOutcomes measure: The change/difference in CatSper expression on day 80, otherOutcomes measure: The change/difference in RANKL expression on day 80, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, city: Copenhagen, country: Denmark, contacts name: Sam Kafai Yahyavi, MD, role: CONTACT, phone: +45 35456360, email: sam.kafai.yahyavi.01@regionh.dk, contacts name: Mads Joon Jorsal, MD, role: CONTACT, phone: +45 38683868, email: mads.joon.jorsal@regionh.dk, contacts name: Sam Kafai Yahyavi, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Mads Joon Jorsal, MD, role: SUB_INVESTIGATOR, geoPoint lat: 55.67594, lon: 12.56553, hasResults: False
protocolSection identificationModule nctId: NCT06300216, orgStudyIdInfo id: KYLL-202401-034-1, briefTitle: A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2027-11-26, completionDateStruct date: 2028-05-26, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Qilu Hospital of Shandong University, class: OTHER, descriptionModule briefSummary: The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients., conditionsModule conditions: Neuroendocrine Tumors, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Octreotide microspheres, outcomesModule primaryOutcomes measure: Treatment Emergent Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Qilu hospital of Shandong University, city: Jinan, state: Shandong, zip: 250012, country: China, contacts name: Jian Wang, Dr., role: CONTACT, phone: 8618560088226, email: wang.jian@sdu.edu.cn, geoPoint lat: 36.66833, lon: 116.99722, hasResults: False
protocolSection identificationModule nctId: NCT06300203, orgStudyIdInfo id: CM310_IIS_SAR07, briefTitle: Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis, acronym: MEGREZ, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2025-05-30, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Beijing Tongren Hospital, class: OTHER, descriptionModule briefSummary: Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease., conditionsModule conditions: Seasonal Allergic Rhinitis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Interleukin-4 receptor responders, interventions name: Placebo, outcomesModule primaryOutcomes measure: Average change from baseline in daily retrospective total nasal symptom score (rTNSS) at week 2., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Tongren Hospital, Capital Medical University, city: Beijing, state: Beijing, zip: 100000, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06300190, orgStudyIdInfo id: Treatment SLAP type IV lesion, briefTitle: Biceps Tenodesis Alone Versus Biceps Tenodesis and Labrum Repair in Superior Labrum Anteroposterior (SLAP) Lesion Type IV, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Aim of this study is comparing results Biceps Tenodesis Alone Versus Biceps Tenodesis and labrum Repair in Superior Labrum Anteroposterior (SLAP) Lesion Type IV, conditionsModule conditions: SLAP Lesion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 2 parallel groups selected by Randomisation, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Aim of this study is comparing outcome results of Biceps Tenodesis Alone Versus Biceps Tenodesis and labrum Repair in Superior Labrum Anteroposterior (SLAP) Lesion Type IV, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Biceps tenodesis alone, interventions name: Biceps tenodesis and labrum repair, outcomesModule primaryOutcomes measure: Clinical outcome by American shoulder elbow score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06300164, orgStudyIdInfo id: Unripecarobinceliac, briefTitle: The Effect of Unripe Carob Fruit in Celiac Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Toros University, class: OTHER, descriptionModule briefSummary: The aim of this study was to investigate the effects of the consumption of cookies produced by adding the unripe part of carob fruit, which has high insoluble fiber, polyphenol and antioxidant content, on the oxidative parameters (TAS and MDA), intestinal permeability (zonulin, GIP) and microbiota of celiac patients and to develop new products containing unripe carob fruit for celiac patients in this direction., conditionsModule conditions: Celiac Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The study will conduct by using a prospective randomized double-blind clinical trial model., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: Participants will not know which type of cookies to eat., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Unripre Carob, outcomesModule primaryOutcomes measure: Examination of between group differences regarding serum Total Antioxidant Capacity (TAC), primaryOutcomes measure: Examination of between group differences regarding serum Malondialdehyde (MDA), primaryOutcomes measure: Examination of between group differences regarding serum zonulin, secondaryOutcomes measure: Comparison of between group differences regarding serum Total Antioxidant Capacity (TAC), secondaryOutcomes measure: Comparison of between group differences regarding serum Malondialdehyde (MDA), secondaryOutcomes measure: Comparison of between group differences regarding serum zonulin, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 64 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06300125, orgStudyIdInfo id: R1881/23 - L2-015, briefTitle: Percutaneous Cryoablation of Low-risk Early Breast Cancer, acronym: PRECICE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2031-03-01, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, collaborators name: Fondazione Umberto Veronesi, collaborators name: IceCure Medical Ltd., descriptionModule briefSummary: Expand the current evidence base regarding percutaneous cryoablation of early-stage, low-risk breast tumors, integrated into the standard therapeutic pathway with well-defined follow-up data, as well as data on quality of life. Demonstrate, therefore, that the use of percutaneous cryoablation in the treatment of low-risk breast carcinoma is not inferior to surgery when combined with adjuvant radiotherapy and chemotherapy (when necessary). The hypothesis is that cryoablation, being simple and oncologically effective, ensures a better quality of life for the patient (reduced morbidity, no need for general anesthesia, improved cosmetic outcomes) and consequently has a lesser psychological impact, as well as a better cost-benefit ratio compared to the standard surgical approach., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 234, type: ESTIMATED, armsInterventionsModule interventions name: Cryoablation, outcomesModule primaryOutcomes measure: Procedure failure rate, secondaryOutcomes measure: Assessment of subject's quality of life in terms of evaluation of sources of distress, secondaryOutcomes measure: Assessment of subject's satisfaction, secondaryOutcomes measure: Cost-analysis - evaluation of cost of intervention, hospitalization and re-intervention (if applicable), secondaryOutcomes measure: Ipsilateral breast tumor recurrence, secondaryOutcomes measure: Distant metastasis, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Franco Orsi, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False